HIV-Neutralizing Antibodies: Epitope Identification and Significance for Future Vaccine

References

• Weiss R. A., Clapham P. R., Cheingsong-Popov R., Dalgleish A. G., Carne C. A., Weller I. V. D., Tedder R. S. Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients. Nature 1985; 316: 69–72
   PubMed Web of Science ®Google Scholar
• Robert-Guroff M., Brown M., Gallo R. C. HTLV-III neutralizing antibodies in patients with AIDS and AIDS-related complex. Nature 1985; 316: 72–74
   PubMed Web of Science ®Google Scholar
• Clapham P., Nagy K., Weiss R. A. Pseudotypes of human T-cell leukemia virus types 1 and 2: Neutralization by patients' sera. Proc. Natl. Acad. Sci. USA 1984; 81: 2886–2889
   PubMed Web of Science ®Google Scholar
• Robert-Guroff M., Oleske J. M., Connor E. M., Epstein L. G., Minnefor A. B., Gallo R. C. Relationship between HTLV-III neutralizing antibody and clinical status of pediatric acquired immunodeficiency syndrome (AIDS) and AIDS-related complex cases. Ped. Res 1987; 21: 547–550
   PubMedGoogle Scholar
• Robert-Guroff M., Giardina P. J., Robey W. G., Jennings A. M., Naugle C. J., Akbar A. N., Grady R. W., Hilgartner M. W. HTLV-III neutralizing antibody development in transfusion-dependent seropositive patients with B-thalassemia. J. Immunol 1987; 138: 3731–3736
   PubMed Web of Science ®Google Scholar
• Robert-Guroff M., Goedert J. J., Naugle C. J., Jennings A. M., Blattner W. A., Gallo R. C. Spectrum of HIV-1 neutralizing antibodies in a cohort of homosexual men: Results of a 6 year prospective study. AIDS Res. Hum. Retroviruses 1988; 4: 343–350
   Google Scholar
• Weber I. N., Clapham P. R., Weiss R. A., Parker D., Roberts C., Duncan J., Weller I., Carne C., Tedder R. S., Pinching A. J., Cheingsong-Popov R. Human immunodeficiency virus infection in two cohorts of homosexual men: Neutralising sera and association of anti-gag antibody with prognosis. Lancet 1987; i: 119–122
   Google Scholar
• Wendler I., Bienzle U., Hunsmann G. Neutralizing antibodies and the course of HIV-induced disease. AIDS Res. Hum. Retroviruses 1987; 3: 157–163
   PubMed Web of Science ®Google Scholar
• Faulkner-Valle G., De Rossi A., Dalla Gassa O., Chieco-Bianchi L. LAV/HTLV-III neutralizing antibodies in the sera of patients with AIDS, lymphadenopathy syndrome and asymptomatic seropositive individuals. Tumori 1986; 72: 219–224
   Google Scholar
• Sawyer L. A., Katzenstein D. A., Hendry R. M., Boone E. J., Vujcic L. K., Williams C. C., Zeger S. L., Saah A. J., Rinaldo C. R., Phair J. P., Giorgi J. V., Quinnan G. V., Jr. Possible beneficial effects of neutralizing antibodies and antibody-dependent, cell-mediated cytotoxicity in human immunodeficiency virus infection. AIDS Res. Hum. Retroviruses 1990; 3: 341–356
   Google Scholar
• Emini E. A., Eichberg J., Nara P. L., Lewis J. A., Matsushita S., Putney S. D. Neutralization of in vivo HIV-1 Infectivity mediated by in vitro neutralizing antibody. Presented at the V International Conference on AIDS. June 4–9. MontrealCanada 1989, abstract
   Google Scholar
• Matsushita S., Robert-Guroff M., Rusche J., Koito A., Hattori T., Hoshino H., Javaherian K., Takatsuki K., Putney S. Characterization of a human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralizing epitope. J. Virol 1988; 62: 2107–2114
   PubMed Web of Science ®Google Scholar
• Desrosiers R. C., Wyand M. S., Kodama T., Ringler D. J., Arthur L. O., Sehgal R. K., Letvin N. L., King N. W., Daniel M. D. Vaccine protection against simian immunodeficiency virus infection. Proc. Natl. Acad. Sci. USA 1989; 86: 6353–6357
   Google Scholar
• Murphey-Corb M., Martin L. N., Davison-Fairburn B., Montelaro R. C., Miller M., West M., Ohkawa S., Baskin G. B., Zhang J -Y, Putney S. D., Allison A. C., Eppstein D. A. A formalin-inactivated whole SIV vaccine confers protection in macaques. Science 1989; 246: 1293–1297
   PubMed Web of Science ®Google Scholar
• Sarin P. S., Sun D. K., Thornton A. H., Naylor R. H., Goldstein A. L. Neutralization of HTLV-III/LAV replication by antiserum to thymosin α1. Science 1986; 232: 1135–1137
   PubMed Web of Science ®Google Scholar
• Papsidero L. D., Sheu M., Ruscetti F. W. Human immunodeficiency virus type 1-neutralizing monoclonal antibodies which react with pl7 core protein: characterization and epitope mapping. J. Virol 1989; 63: 267–272
   Google Scholar
• Robey W. G., Arthur L. O., Matthews T. J., Langlois A., Copeland T. D., Lerche N. W., Oroszlan S., Bolognesi D. R., Gilden R. V., Fischinger R. J. Prospect for prevention of human immunodeficiency virus infection: purified 120-kDa envelope glycoprotein induces neutralizing antibody. Proc. Natl. Acad. Sci. USA 1986; 83: 7023–7027
   PubMed Web of Science ®Google Scholar
• Lasky L. A., Groopman J. E., Fennie C. W., Benz P. M., Capon D. J., Dowbenko D. J., Nakamura G. R., Nunes W. M., Renz M. E., Berman P. W. Neutralization of the AIDS retrovirus by antibodies to a recombinant envelope glycoprotein. Science 1986; 233: 209–212
   PubMed Web of Science ®Google Scholar
• Rusche J. R., Lynn D. L., Robert-Guroff M., Langlois A. J., Lyerly H. K., Carson H., Krohn K., Ranki A., Gallo R. C., Bolognesi D. R., Putney S. D., Matthews T. J. Humoral immune response to the entire human immunodeficiency virus envelope glycoprotein made in insect cells. Proc. Natl. Acad. Sci. USA 1987; 84: 6924–6928
   Google Scholar
• Earl P. L., Robert-Guroff M., Matthews T. J., Krohn K., London W. T., Moss B. Isolate- and group-specific immune responses to the envelope protein of human immunodeficiency virus induced by a live recombinant vaccinia virus in Macaques. AIDS Res. Hum. Retroviruses 1989; 5: 23–32
   Google Scholar
• Putney S. D., Matthews T. J., Robey W. G., Lynn D. L., Robert-Guroff M., Mueller W. T., Langlois A. J., Ghrayeb J., Petteway S. R., Jr., Weinhold K. J., Fischinger R. J., Wong-Staal E., Gallo R. C., Bolognesi D. R. HTLV-III/LAV-neutralizing antibodies to an E. coli-produced fragment of the virus envelope. Science 1986; 234: 1392–1395
   PubMed Web of Science ®Google Scholar
• Palker T J., Clark M. E., Langlois A. J., Matthews T. J., Weinhold K. J., Randall R. R., Bolognesi D. R., Haynes B. F. Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides. Proc. Natl. Acad. Sci. USA 1988; 85: 1932–1936
   PubMed Web of Science ®Google Scholar
• Rusche J. R., Javaherian K., McDanal C., Petro J., Lynn D. L., Grimaila R., Langlois A., Gallo R. C., Arthur L. O., Fischinger P. J., Bolognesi D. P., Putney S. D., Matthews T. J. Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120. Proc. Natl. Acad. Sci. USA 1988; 85: 3198–3202
   PubMed Web of Science ®Google Scholar
• Goudsmit J., Debouck C., Meloen R. H., Smit L., Bakker M., Asher D. M., Wolff A. V., Gibbs C. J., Jr., Gajdusek C. Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees. Proc. Natl. Acad. Sci. USA 1988; 85: 4478–4482
   PubMed Web of Science ®Google Scholar
• Modrow S., Hahn B. H., Shaw G. M., Gallo R. C., Wong-Staal E., Wolf H. Computer-assisted analysis of envelope protein sequences of seven human immunodeficiency virus isolates; prediction of antigenic epitopes in conserved and variable regions. J. Virol 1987; 61: 570–578
   PubMed Web of Science ®Google Scholar
• Kinney Thomas E., Weber J. N., McClure J., Clapham P. R., Singhal M. C., Shriver M. K., Weiss R. A. Neutralizing monoclonal antibodies to the AIDS virus. AIDS 1988; 2: 25–29
   Google Scholar
• Fung M. S. C., Sun C., Sun N. -C, Chang N. T., Chang T. W. Monoclonal antibodies that neutralize HIV-1 virions and inhibit syncytium formation by infected cells. Bio/Technology 1987; 5: 940–946
   Google Scholar
• Skinner M. A., Ting R., Langlois A. J., Weinhold K. J., Lyerly H. K., Javaherian K., Matthews T. J. Characteristics of a neutralizing monoclonal antibody to the HIV envelope glycoprotein. AIDS Res. Hum. Retroviruses 1988; 4: 187–197
   PubMed Web of Science ®Google Scholar
• Linsley R. S., Ledbetter J. A., Kinney-Thomas E., Hu S. -L. Effects of anti-gpl20 monoclonal antibodies on CD4 receptor binding by the env protein of human immunodeficiency virus type 1. J. Virol 1988; 62: 3695–3702
   PubMedGoogle Scholar
• Broliden P. A., Ljunggren K., Hinkula J., Norrby E., Akerblom L., Wahren B. A. Monoclonal antibody to human immunodeficiency virus type 1 which mediates cellular cytotoxicity and neutralization. J. Virol 1990; 64: 936–940
   PubMedGoogle Scholar
• Javaherian K., Langlois A. J., McDanal C., Ross K. L., Eckler L. I., Jellis C. L., Profy A. T., Rusche J. R., Bolognesi D. P., Putney S. D., Matthews T. J. Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. Proc. Natl. Acad. Sci. USA 1989; 86: 6768–6772
   PubMed Web of Science ®Google Scholar
• Putney S. D., LaRosa G., Javaherian K., Emini E., Bolognesi D., Matthews T. Development of an HIV. subunit vaccine. Presented at the V International Conference on AIDS. June 4–9. MontrealCanada 1989, abstract
   Google Scholar
• Hattori T., Koito A., Takatsuki K., Kido H., Katunuma N. Involvement of tryptase-related cellular protease(s) in human immunodeficiency virus type 1 infection. FEBS Lett 1989b; 248: 48–52
   PubMed Web of Science ®Google Scholar
• Stephens P. E., Clements G., Yarranton G. T. A chink in HIV's armour?. Nature 1990; 343: 219
   PubMedGoogle Scholar
• Weiss R. A., Clapham R. R., Weber J. N., Dalgleish A. G., Lasky L. A., Berman P. W. Variable and conserved neutralization antigens of human immunodeficiency virus. Nature 1986; 324: 572–575
   PubMed Web of Science ®Google Scholar
• Ho D. D., Sarngadharan M. G., Hirsch M. S., Schooley R. T., Rota T. R., Kennedy R. C., Chanh T. C., Sato V. L. Human immunodeficiency virus neutralizing antibodies recognize several conserved domains on the envelope glycoproteins. J. Virol 1987; 61: 2024–2028
   PubMed Web of Science ®Google Scholar
• Lasky L. A., Nakamura G., Smith D. H., Fennie C., Shimasaki C., Patzer E., Berman P., Gregory T., Capon D. J. Delineation of a region of the human immunodeficiency virus type 1 gpl20 glycoprotein critical for interaction with the CD4 receptor. Cell 1987; 50: 975–985
   PubMed Web of Science ®Google Scholar
• Schrier R. D., Gnann J. W., Jr., Langlois A. J., Shriver K., Nelson J. A., Oldstone M. B. A. B- and T-lymphocyte responses to an immunodominant epitope of human immunodeficiency virus. J. Virol 1988; 62: 2531–2536
   PubMedGoogle Scholar
• Michel M. -L., Mancini M., Sobczak E., Favier V., Guetard D., Bahraoui E. M., Tiollais R. Induction of anti-human immunodeficiency virus (HIV) neutralizing antibodies in rabbits immunized with recombinant HIV-hepatitis B surface antigen particles. Proc. Natl. Acad. Sci. USA 1988; 85: 7957–7961
   PubMedGoogle Scholar
• Sun N. -C, Ho D. D., Sun C. R. Y., Liou R. -S., Gordon W., Fung M. S. C., Li X. -L., Ting R. C., Lee T. -H., Chang N. T., Chang T. -W. Generation and characterization of monoclonal antibodies to the putative CD4-binding domain of human immunodeficiency virus type 1 gpl20. J. Virol 1989; 63: 3579–3585
   PubMed Web of Science ®Google Scholar
• Chanh T. C., Dreesman G. R., Kanda R., Linette G. R., Sparrow J. T., Ho D. D., Kennedy R. C. Induction of anti-HIV neutralising antibodies by synthetic peptides. EMBO J 1986; 5: 3065–3071
   Web of Science ®Google Scholar
• Dalgleish A. G., Chanh T. C., Kennedy R. C., Kanda P., Clapham R. R., Weiss R. A. Neutralization of diverse HIV-1 strains by monoclonal antibodies raised against a gp4l synthetic peptide. Virology 1988; 165: 209–215
   Google Scholar
• Evans D. J., McKeating J., Meredith J. M., Burke K. L., Katrak K., John A., Ferguson M., Minor P. D., Weiss R. A., Almond J. W. An engineered poliovirus chimaera elicits broadly reactive HIV-l neutralizing antibodies. Nature 1989; 339: 385–388
   PubMed Web of Science ®Google Scholar
• Ho D. D., Kaplan J. C., Rackauskas I. E., Gurney M. E. Second conserved domain of gpl20 is important for HIV infectivity and antibody neutralization. Science 1988; 239: 1021–1023
   PubMedGoogle Scholar
• Geysen H. M., Meleon R. H., Barteling S. I. Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid. Proc. Nail. Acad. Sci. USA 1984; 81: 3998–4002
   PubMed Web of Science ®Google Scholar
• vanTijn D. A., Boucher C. A. B., Bakker M., Goudsmit J. Antigenicity of linear B-cell epitopes in the CI, VI, and V3 region of HIV-1 gpl20. JAIDS 1989; 2: 303–306
   Google Scholar
• Rossi P., Moschese V., Broliden P. A., Fundaro C., Quinti I., Plebani A., Giaquinto D., Tovo P. A., Ljunggren K., Rosen J., Wigzell H., Jondal M., Wahren B. Presence of maternal antibodies to human immunodeficiency virus 1 envelope glycoprotein gpl20 epitopes correlates with the uninfected status of children born to seropositive mothers. Proc. Natl. Acad. Sci. USA 1990; 86: 8055–8058
   Google Scholar
• Goedert X. J., Mendez H., Drummond J. E., Robert-Guroff M., Minkoff H. L., Holman S., Stevens R., Rubinstein A., Blattner W. A., Willoughby A., Landesman S. H. Mother-to-infant transmission of human immunodeficiency virus type 1: Association with prematurity or low anti-gpl20. Lancet 1989; ii: 1351–1354
   Google Scholar
• Klasse E. J., Pipkorn R., Blomberg J. Presence of antibodies to a putatively immunosuppressive part of human immunodeficiency virus (HIV) envelope glycoprotein gp41 is strongly associated with health among HIV-positive subjects. Proc. Natl. Acad. Sci. USA 1988; 85: 5225–5229
   PubMed Web of Science ®Google Scholar
• Cianciolo G. J., Bogerd H., Snyderman R. Human T-cell lymphotropic virus (HTLV) envelope-related peptides inhibit human lymphocyte proliferative responses. Clin. Res 1986; 34: 492A, abstract
   Google Scholar
• Hahn B. H., Gonda M. A., Shaw G. M., Popovic M., Hoxie J. A., Gallo R. C., Wong-Staal E. Genomic diversity of the acquired immune deficiency syndrome virus HTLV-III: different viruses exhibit greatest divergence in their envelope genes. Proc. Natl. Acad. Sci. USA 1985; 82: 4813–4817
   Google Scholar
• Hahn B. H., Shaw G. M., Taylor M. E., Redfield R. R., Markham E. D., Salahuddin S. Z., Wong-Staal E., Gallo R. C., Parks E. S., Parks W. P. Genetic variation in HTLV-III/LAV over time in patients with AIDS or at risk of AIDS. Science 1986; 232: 1548–1554
   PubMed Web of Science ®Google Scholar
• Saag M. S., Hahn B. H., Gibbons J., Li Y., Parks E. S., Parks W. R., Shaw G. M. Extensive variation of human immunodeficiency virus type-1 in vivo. Nature 1988; 334: 440–444
   PubMedGoogle Scholar
• Fisher A. G., CoUalti E., Ratner L., Gallo R. C., Wong-Staal E. A molecular clone of HTLV-III with biologic activity. Nature 1985; 316: 262–265, abstract
   PubMed Web of Science ®Google Scholar
• Robert-Guroff M., Reitz M. S., Robey W. G., Gallo R. C. In vitro generation of an HTLV-III variant by neutralizing antibody. J. Immunol 1986; 137: 3306–3309
   PubMed Web of Science ®Google Scholar
• Nara P. L., Goudsmit J. Neutralization resistant variants of HIV-1 escape via the hypervariable immunodominant V3 region (303–331 aa): evidence for a conformational neutralization epitope. Vaccines 90, R. A. Lerner, H. Ginsberg, R. M. Chanock, E. Brown. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 1990
   Google Scholar
• Kono Y., Kobayashi K., Eukunaga Y. Antigenic drift of equine infectious anemia virus in chronically infected horses. Arch. Virusforschung 1973; 41: 1–10
   PubMedGoogle Scholar
• Montelaro R. C., Parekh B., Orrego A., Issel C. J. Antigenic variation during persistent infection by equine infectious anemia virus, a retrovirus. J. Biol. Chem 1984; 259: 10539–10544
   PubMedGoogle Scholar
• Narayan O., Clements J. E., Griffin D. E., Wolinsky J. S. Neutralizing antibody spectrum determines the antigenic profiles of emerging mutants of visna virus. J. Virol 1981; 32: 1045–1050
   Google Scholar
• Scott J. v., Stowring L., Haase A. T., Narayan O., Vigne R. Antigenic variation in visna virus. Cell 1979; 18: 321–327
   Google Scholar
• Reitz M. S., Jr., Wilson C., Naugle C., Gallo R. C., Robert-Guroff M. Generation of a neutralization-resistant variant of HIV-1 isdue to selection for a point mutation in the envelope gene. Cell 1988; 54: 57–63
   PubMed Web of Science ®Google Scholar
• Wilson C., Reitz M. S., Jr., Aldrich K., Klasse E. J., Blomberg J., Gallo R. C., Robert-Guroff M. The site of an immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 does not constitute the neutralization epitope. J. Virol 1990; 64: 3240–3248
   Google Scholar
• Pinter A., Honnen W. J., Tilley S. A., Bona C., Zaghouani H., Gorny M. K., Zolla-Pazner S. Oligomeric structure of gp41, the transmembrane protein of human immunodeficiency virus type 1. J. Virol 1989; 63: 2674–2679
   Google Scholar
• Earl P. L., Doms R. W., Moss B. Oligomeric structure of the human immunodeficiency virus type 1 envelope glycoprotein. Proc. Natl. Acad. Sci. USA 1990; 87: 648–652
   PubMed Web of Science ®Google Scholar
• Lee T. -H., Syu W. -J, Chou M. -J, Essex M. Immunodominant epitopes of HIV-1 gpl20: A possible obstacle for vaccine development. Vaccines 89, R. A. Lerner, H. Ginsberg, R. M. Chanock, E. Brown. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 1989; 191–194
   Google Scholar
• Dowbenko D., Nakamura G., Fennie C., Shimasaki C., Riddle L., Harris R., Gregory T., Lasky L. Epitope mapping of the human immunodeficiency virus type 1 gpl20 with monoclonal antibodies. J. Virol 1988; 62: 4703–4711
   Google Scholar
• Kowalski M., Potz J., Basiripour L., Dorfman T., Goh W. C., Terwilliger E., Dayton A., Rosen C., Haseltine W., Sodroski J. Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1. Science 1987; 237: 1351–1355
   PubMed Web of Science ®Google Scholar
• Willey R. L., Smith D. H., Lasky L. A., Theodore T. S., Earl P. L., Moss B., Capon D. I., Martin M. A. In vitro mutagenesis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity. J. Virol 1988; 62: 139–147
   PubMed Web of Science ®Google Scholar
• Willey R. L., Ross E. K., Buckler-White A. J., Theodore T. S., Martin M. A. Functional interaction of constant and variable domains of human immunodeficiency virus type 1 gpl20. J. Virol 1989; 63: 3595–3600
   PubMedGoogle Scholar
• Looney D. J., Fisher A. G., Putney S. D., Rusche J. R., Redfield R. R., Burke D. S., Gallo R. C., Wong-Staal E. Type-restricted neutralization of molecular clones of human immunodeficiency virus. Science 1988; 241: 357–359
   PubMed Web of Science ®Google Scholar
• Myers G., Rabson A. B., Josephs S. E., Smith T. E., Wong-Staal E., Berzofsky J. A. Human Retroviruses and AIDS. Los Alamos National Laboratory, Los Alamos, NM 1989, 1989
   Google Scholar
• Gallaher W. R. Detection of a fusion peptide sequence in the transmembrane protein of human immunodeficiency virus. Cell 1987; 50: 327–328
   PubMed Web of Science ®Google Scholar
• Gallaher W. R., Ball I. M., Garry R. E., Griffin M. C., Montelaro R. C. A general model for the transmembrane proteins of HIV and other retroviruses. AIDS Res. Hum. Retroviruses 1989; 5: 431–440
   PubMed Web of Science ®Google Scholar
• Costing L. H., McClure J., Dickinson E. S., Watanabe S. M., Shriver K., Goldstein L. C. Monoclonal antibodies to gpllO and gp41 of human immunodeficiency virus. J. Clin. Microbiol 1987; 25: 845–848
   Google Scholar
• Palker T. J., Matthew T. J., Clark M. E., Cianciolo G. J., Randall R. R., Langlois A. J., White G. C., Safai B., Snyderman R., Bolognesi D. P., Haynes B. E. A conserved region at the COOH terminus of human immunodeficiency virus gp120 envelope protein contains an immunodominant epitope,. Proc. Natl. Acad. Sci. USA 1987; 84: 2479–2483
   PubMed Web of Science ®Google Scholar
• Banapour B., Rosenthal K., Rabin L., Sharma V., Young L., Fernandez J., Engleman E., McGrath M., Reyes G., Lifson J. Characterization and epitope mapping of a human monoclonal antibody reactive with the envelope glycoprotein of human immunodeficiency virus. J. Immunol 1987; 139: 4027–4033
   PubMed Web of Science ®Google Scholar
• Ratner L., Haseltine W., Patarca R., Livak K. J., Starcich B., Josephs S. E., Doran E. R., Rafalski J. A., Whitehorn E. A., Baumeister K., Ivanoff L., Petteway S. R., Jr, Pearson M. L., Lautenberger J. A., Papas T. S., Ghrayeb J., Chang N. T., Gallo R. C., Wong-Staal F. Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature 1985; 313: 277–284
   PubMed Web of Science ®Google Scholar